Roche’s Alecensa Goes Up Against Zykadia with First-Line NSCLC US FDA Approval

Expanded US approval for Alecensa in ALK-positive NSCLC will stand the product in good stead as it helps make up for upcoming biosimilar threat to Avastin, Rituxan and Herceptin.

Swimmers swimming in lanes
Alecensa has a competitive edge in ALK-positive NSCLC • Source: Shutterstock

The US FDA has approved an expanded indication for Roche’s second-generation anaplastic lymphoma kinase (ALK) inhibitor, Alecensa (alectinib), which the company hopes will mean it can transform the standard of care for the treatment of people with ALK-positive metastatic non-small cell lung cancer (NSCLC). The drug is a key plank in the company’s defense against encroaching generic competition to its flagship products, Avastin (bevacizumab), Rituxan (rituximab) and Herceptin (trastuzumab).

The approval, based on the ALEX study, means it can be used upfront in patients with ALK-positive NSCLC as detected...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from New Products

Biogen Edges Closer To Growth On Strong Q2

 

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.

PTC To Challenge BioMarin In PKU With Oral Sephience

 
• By 

PTC plans to compete with BioMarin’s two phenylketonuria drugs with efficacy data showing strong reduction of phenylalanine and ability for patients to liberalize their diets.

Apellis’ Empaveli Expansion Underway In Rare Kidney Disease

 

The US FDA approved the complement C3 inhibitor for new indications in C3G and primary IC-MPGN, providing a new growth opportunity for Apellis.

Analysts Not Impressed With Adaptimmune’s Survival Attempts

 
• By 

The company is getting just $55m from the sale of Tecelra and a couple of late-stage T-cell therapies to US WorldMeds.

More from Scrip

Frazier Life Sciences Raises $1.3bn To Fund Start-Ups Through Value-Creating Data

 
• By 

Frazier Life Sciences will invest 40%-50% of its new venture capital fund in new biopharma companies financed to develop preclinical drug candidates through clinical proof of concept and, hopefully, M&A.

Executives On The Move: Four New CEOs Among This Week’s Changes

Recent moves in the industry include C-suite changes at Galapagos, plus Bristol Myers Squibb gets a new CMO from AstraZeneca.

Sanofi CFO Says Direct Sales To Patients ‘Certainly Worth Considering’

 
• By 

François Roger believes fixing inefficiencies is more important than playing with pricing.